Atrogi

Executive Summary

Atrogi is a Swedish biotech company advancing first-in-class small molecule therapies to transform metabolic health, with a focus on muscular wasting and diabetes. The company is phase II ready, positioning it to initiate clinical trials for its lead candidate targeting conditions that affect hundreds of millions globally. By addressing unmet needs in muscle preservation and glycemic control, Atrogi’s platform has the potential to redefine standard of care in metabolic diseases and beyond. With a lean structure and a clear path to clinical development, Atrogi represents a high-upside opportunity in the metabolic space. The company’s phase II readiness de-risks its near-term trajectory, while its novel mechanism offers differentiation in a crowded market. Success would depend on execution and clinical data, but the underlying science and market need are compelling.

Upcoming Catalysts (preview)

• Q2 2026Phase II clinical trial initiation80% success
• Q3 2026Partnership or licensing deal for lead candidate40% success
• Q4 2026Presentation of preclinical or phase I data at a major conference60% success